OTCMKTS:TRLPF Acerus Pharmaceuticals (TRLPF) Stock Price, News & Analysis → Special FREE offer on stock hotsheets (From DTI) (Ad) Free TRLPF Stock Alerts $0.22 0.00 (0.00%) (As of 07/21/2023) Add Compare Share Share Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.08▼$0.34VolumeN/AAverage Volume5,474 shsMarket Capitalization$56.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Acerus Pharmaceuticals alerts: Email Address Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About Acerus Pharmaceuticals Stock (OTCMKTS:TRLPF)Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More TRLPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRLPF Stock News HeadlinesFebruary 8, 2024 | wsj.comTakeda Pharmaceutical Co. Ltd. ADRJanuary 1, 2023 | seekingalpha.com2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To BenefitMay 5, 2024 | InvestorPlace (Ad)The Next Nvidia Could Secure Your Retirement2023 was the year of AI. You almost couldn't fail if you were investing with AI in mind. But winning in 2024 will require you to find the next big narrative. And there's one algorithm best suited to finding the next big trend.August 9, 2022 | financialpost.comAcerus Reports Second Quarter 2022 Financial ResultsMarch 15, 2022 | financialpost.comAcerus Reports Fourth Quarter and Full Year 2021 Financial ResultsSee More Headlines Receive TRLPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2018Today5/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:TRLPF CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,790,000.00 Net Margins-254.66% Pretax MarginN/A Return on Equity-346.72% Return on Assets-94.54% Debt Debt-to-Equity Ratio0.64 Current Ratio1.35 Quick Ratio0.90 Sales & Book Value Annual Sales$7.38 million Price / Sales7.71 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares258,615,000Free FloatN/AMarket Cap$56.90 million OptionableNot Optionable Beta2.60 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Patricia SymmesChief Operating OfficerDr. Nathan BrysonChief Scientific OfficerMr. Philippe SavardVP, Gen. Counsel & Corp. Sec.Mr. Edward GudaitisPres , CEO & DirectorMr. Robert M. MotzChief Financial OfficerKey CompetitorsAnnovis BioNYSE:ANVSEagle PharmaceuticalsNASDAQ:EGRXCheckpoint TherapeuticsNASDAQ:CKPTCleneNASDAQ:CLNNReneo PharmaceuticalsNASDAQ:RPHMView All Competitors TRLPF Stock Analysis - Frequently Asked Questions How have TRLPF shares performed in 2024? Acerus Pharmaceuticals' stock was trading at $0.22 on January 1st, 2024. Since then, TRLPF stock has increased by 0.0% and is now trading at $0.22. View the best growth stocks for 2024 here. How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) announced its quarterly earnings data on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). The specialty pharmaceutical company had revenue of $1.58 million for the quarter. Acerus Pharmaceuticals had a negative trailing twelve-month return on equity of 346.72% and a negative net margin of 254.66%. How do I buy shares of Acerus Pharmaceuticals? Shares of TRLPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TRLPF) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance Gold“Crash Insurance” For Your RetirementUnstoppable ProsperityBiden Nomination CANCELED?The Freeport SocietyWarren Buffet Stockpiling Gold?Reagan Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.